14 February 2024 in European Journal of Nuclear Medicine and Molecular Imaging
28 March 2020 in Pediatric Hematology/Oncology and Immunopathology
¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy is widely used for the detection and staging of neuroblastoma. Risk-adapted treatment in patients with neuroblastic tumors is based on many clinical and genetic factors including histopathology. Purpose: non-invasive prediction of an unfavorable histological variant in patients with neuroblastic tumors using quantitative assessment of ¹²³I-MIBG uptake. This study was approved by the Independent Ethical Committee and the Academic Council of Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation. 96 patients were included in this retrospective study. ¹²³I-MIBG-scintigraphy including whole body planner images and SPECT/CT were performed for all patients before any type of treatment. Semiquantitative and quantitative assessment of ¹²³I-MIBG uptake were calculated and analyzed. Out of 96 patients: 54 with neuroblastoma (NB), 28 with ganglioneuroblastoma (GNB) and 14 with ganglioneuroma (GN). The average values of TLCRR and SUVmax for NB were 5.67 and 7.5, for GNB – 2.58 and 3.1 and for GN – 1.48 and 1.85, respectively. A centile analysis was carried out for all groups. SPECT/CT in combination with modern software allows semiquantitative and quantitative assessment of ¹²³I-MIBG uptake in neuroblastic tumor. The TLCRR and SUVmax can be used separately as well as in combination with NSE for prediction of histological variant.
1 June 2023 in Pediatria. Journal named after G.N. Speransky
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Prescriptions for the positron emission tomography-computed tomography (PET-CT) in adult cancer patients are based on the results of multicenter studies, systematic reviews, and meta-analyses. Thus, published international guidelines help nuclear medicine specialists, oncologists and radiologists in determining the most appropriate diagnostic algorithms for each patient with the purpose of selecting the most appropriate treatment as well as allowing the introduction of the new prognostic factors. Compared with adult patients, the use of PET-CT in pediatric oncology is somewhat limited due to the lack of systematic, large multicenter studies and, therefore, precise and clear guidelines. The reasons for the lack of the large studies may be the relatively low incidence of malignant neoplasms in pediatric practice and the fear for the delayed effects of exposure of ionizing radiation on the growing child's body. The purpose of this bibliographical review was to provide a summary of the use and the role of PET-CT in children with the most frequent malignancies.
28 May 2021 in Pediatria. Journal named after G.N. Speransky
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
+1
In adults with oncological diseases, most PET/CT studies with 18F-FDG are performed using a scanning protocol with a reduced scanning area (r-PET/CT). In pediatric oncology, PET/CT with 18F-FDG is recommended to be performed in the «whole body» mode. We hypothesized that the use of r-PET/CT in children with Hodgkin's lymphoma (HL) may be sufficient without loss of diagnostic value. Materials and methods of research: a comparative analysis of PET/CT scanning protocols in «whole body» mode and r-PET/CT mode in children with HL was carried out. The retrospective analysis included 105 patients aged 0–18 years. All patient underwent primary whole-body PET/CT examinations at the time of initial staging and intermediate follow-up PET/CT scan after 2-cycle of chemotherapy. 210 PET/CT studies were retrospectively analyzed. Results: in 94 (89,5%) of 105 patients the identified lesions were localized within the area of the field-of-view of r-PET/CT, and additional lesions detected in 11 (10,5%) patients in the whole-body PET/CT examinations have not affected the results of staging and management. Conclusion: the detection of additional foci of pathological metabolic activity beyond r-PET/CT has no further impact on the stage of the disease, the protocol of treatment and the evaluation of the early response to the therapy. The advantage of r-PET/CT protocol is the reduction in radiation exposure and study time, which is very important for pediatric patients with HL.
1 December 2021 in Pediatric Hematology/Oncology and Immunopathology
The value of single-photon emission computed tomography combined with computed tomography imaging in ¹²³I-Metaiodobenzylguanidine scintigraphy in children with neuroblastomaWhole body scintigraphy with ¹²³I-Metaiodobenzylguanidine (¹²³I-MIBG) is an important imaging modality for evaluation of patients with neuroblastoma (NB). As the intrinsic nuclear scintigraphic characteristics, the assessment of conventional planar ¹²³I-MIBG images presents some difficulties. The limited resolution of planar images can induce false-negative results for small lesions, whereas the presence of physiologic MIBG uptake is not always easily differentiable from pathologic uptake and can induce false-positive results. Single-photon emission computed tomography combined with computed tomography (SPECT/ CT) hybrid imaging technique, allowing the direct fusion of morphologic and functional information, has been suggested to be more accurate. However, SPECT/CT imaging renders slightly more radiation to patients from CT portion of the study and is time consuming. The aim of our study was to investigate how much SPECT/CT can have additional diagnostic value over planar imaging in NB patients at initial staging. The study was approved by the Independent Ethics Committee and the Scientific Council of the D. Rogachev NMRCPHOI. A total of 251 SPECT/CT scans following by planar ¹²³I-MIBG imaging scans performed in 251 patients with NB were retrospectively analyzed. In 72.1% of the studies, the whole-body planar images and SPECT/CT images showed the same result. In 27.9% of studies, however, SPECT/CT images provided additional very important information. In our study, the diagnosis reached by planar imaging was revised or specified by SPECT/CT in 70 of the 251 patients and was clinically significant.
12 January 2019 in Pediatric Hematology/Oncology and Immunopathology
123I-MIBG (metaiodobenzylguanidine) scintigraphy and 99mTc-MDP bone scintigraphy (bone scan) are widely used in diagnosis and staging of NB. Consecutively using both methods lead to overall radiation exposure. As most of the patients need additional anesthesia to perform these diagnostic procedures, which accordingly increase the side effect, workload and expenditure. To minimize the exposure, side effect, workload and expenditure, we set the tasks to optimize the diagnostic algorithm. Determine the indications of bone scan after 123I-MIBG scintigraphy. Materials and Methods: 129 patients with NB were included in retrospective study who underwent both diagnostic procedures at interval of less than 30 days at the stage of initial diagnostic procedure using standard protocols. Out of 83 MIBG positive patients bone scan was able to detect metastatic lesions only in 48 patients. However, bone scan had revealed metastatic lesions in 3 out of 14 MIBG-negative patients. Bone scan is indicated only in MIBG-negative neuroblastoma patients; and in cases where the MIBG uptake cannot be determined for example after operative treatment or after starting of chemotherapy.